Form 4: IRADIMED CEO Sells Shares Under 10b5-1 Plan

IRADIMED's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock for approximately $463,700 through a pre-arranged 10b5-1 trading plan.

Summary

• Roger E. Susi, the CEO, President, and Chairman of IRADIMED CORP, reported the sale of 5,000 shares of the company's common stock.
• The sales occurred on December 1, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Susi on June 16, 2025.
• The transactions involved two separate sales: 1,676 shares at a weighted average price of $92.34 per share and 3,324 shares at a weighted average price of $92.97 per share.
• The total proceeds from these sales are approximately $463,700.
• The shares sold were indirectly owned through the Phillip Susi 2008 Dynasty Trust.
• Following these transactions, Mr. Susi's indirect beneficial ownership through the Phillip Susi 2008 Dynasty Trust stands at 2,302,500 shares.
• Mr. Susi also indirectly beneficially owns 162,950 shares via the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust, though he disclaims beneficial ownership of the latter except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral, as the sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a planned liquidity event for personal financial management rather than a reaction to new material non-public information or a change in management's confidence in the company's prospects.

Negatives

• Roger E. Susi, a key executive and director, sold 5,000 shares of company common stock.

Future Outlook

This filing reports a historical insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction report is specific to IRADIMED CORP and its CEO, Roger E. Susi. It does not provide information directly related to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: May observe a reduction in direct insider holdings; however, the pre-planned nature of the sale under Rule 10b5-1 typically lessens concerns about management's confidence in the company's future, as these sales are scheduled in advance.

Key Dates

Recommendation

The filing reports a pre-scheduled insider sale by the CEO under a Rule 10b5-1 plan. Such sales are typically for personal financial planning and do not necessarily reflect a change in management's outlook on the company's future performance. Given the planned nature of the transaction and the relatively small percentage of total holdings sold, it does not provide a strong signal for either buying or selling, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

IRADIMED, IRMD, insider trading, Form 4, stock sale, CEO, director, 10b5-1 plan, beneficial ownership